Browsing Tag
subcutaneous biologics
2 posts
Can HYMPAVZI change hemophilia care for patients with inhibitors? Pfizer’s Phase 3 results signal a new standard
Pfizer’s HYMPAVZI showed 93% fewer bleeds in hemophilia patients with inhibitors. Explore how this subcutaneous treatment could redefine care standards.
Halozyme Therapeutics (HALO) completes $900m Elektrofi deal—what’s next for its royalty roadmap?
Halozyme finalizes $900M Elektrofi deal to strengthen its subcutaneous biologics platform. Discover how this move impacts future royalties and delivery formats.